Known targets — ChEMBL curated mechanism
ADRA2AADRA2BADRA2CADRB2AGTR1AVPR1AAVPR1BAVPR2BDKRB2CALCRCHRNA3CHRNB4ESR1ESR2GHSRGNRHRGSC1HSPA8MALT1MC1RMC4RNOS1NOS2NOS3OPRK1OXTRRAMP1RAMP2RAMP3SCN5ASSTR1SSTR2SSTR3SSTR4SSTR5dacAdacBdacCfolPftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Acetic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR1 known ✓ | P30556 | 1/20 | 0.35 |
| ▸ | FFAR3 | O14843 | 3/20 | 0.50 |
| ▸ | LCK | P06239 | 1/20 | 0.50 |
| ▸ | FYN | P06241 | 1/20 | 0.50 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.44 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.44 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.44 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.44 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.41 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.39 |
| ▸ | PAOX | Q6QHF9 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.35 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.35 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 3/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acetic Acid SCHEMBL28664565 | 1.00 | FFAR3 (0.50) | FFAR3LCKFYNCHRM2CHRM4 | |
| Acetic Acid SCHEMBL22152 | 1.00 | FFAR3 (0.50) | FFAR3LCKFYNCHRM2CHRM4 | |
| Acetic Acid SCHEMBL28289424 | 1.00 | FFAR3 (0.50) | FFAR3LCKFYNCHRM2CHRM4 | |
| Acetic Acid SCHEMBL28549045 | 1.00 | FFAR3 (0.50) | FFAR3LCKFYNCHRM2CHRM4 | |
| Acetic Acid SCHEMBL31218573 | 1.00 | FFAR3 (0.50) | FFAR3LCKFYNCHRM2CHRM4 | |
| Acetic Acid SCHEMBL19356582 | 1.00 | FFAR3 (0.50) | FFAR3LCKFYNCHRM2CHRM4 | |
| Acetic Acid SCHEMBL6368562 | 0.97 | FFAR3 (0.47) | FFAR3LCKFYNCHRM2CHRM4 | |
| Acetic Acid SCHEMBL20577632 | 0.97 | FFAR3 (0.47) | FFAR3LCKFYNCHRM2CHRM4 | |
| Acetic Acid SCHEMBL9319460 | 0.97 | FFAR3 (0.47) | FFAR3LCKFYNCHRM2CHRM4 | |
| Acetic Acid SCHEMBL2282544 | 0.97 | FFAR3 (0.47) | FFAR3LCKFYNCHRM2CHRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180066009-A1 | Nucleosides and Oligonucleotides for Studies on Reversal of Cytotoxic and Mutagenic Damage of DNA and as Diagnostics Tools | CHEMGENES CORP (US) | 2018-03-08 | — | — | US | disclosed |
| US-9718855-B2 | Nucleosides and oligonucleotides for studies on reversal of cytotoxic and mutagenic damage of DNA and as diagnostics tools | CHEMGENES CORPORATION (US) | 2017-08-01 | — | — | US | disclosed |
| US-20140350234-A1 | Nucleosides and Oligonucleotides for Studies on Reversal of Cytotoxic and Mutagenic Damage of DNA and as Diagnostics Tools | CHEMGENES CORPORATION (US) | 2014-11-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140350234-A1 | Nucleosides and Oligonucleotides for Studies on Reversal of Cytotoxic and Mutagenic Damage of DNA and as Diagnostics Tools | UNG, OGG1, ADAR | AGTR1 2211/4885FFAR3 2932/4885LCK 3766/4885 |
| US-20180066009-A1 | Nucleosides and Oligonucleotides for Studies on Reversal of Cytotoxic and Mutagenic Damage of DNA and as Diagnostics Tools | UNG, OGG1, ADAR | AGTR1 2211/4885FFAR3 2932/4885LCK 3766/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.